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Abstract
Background: Adherence is a necessary part of successful antiretroviral treatment (ART). We assessed risk factors for
incomplete adherence among a cohort of HIV-infected women initiating ART and examined associations between
adherence and virologic response to ART.
Methods: A secondary data analysis was conducted on a cohort of 154 women initiating non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based ART at a single site in Johannesburg, South Africa. Ninety women had been
enrolled in a prevention of mother-to-child transmission (pMTCT) program and were exposed to single-dose
nevirapine (sdNVP) >18 months earlier. Women were interviewed pre-treatment and clinical, virologic and
adherence data were collected during follow-up to 24 weeks. Incomplete adherence to ART was defined as
returning >5% of medications, estimated by pill counts at scheduled visits. Multivariable logistic regression analysis
and unadjusted odds ratio (95%CI) were performed, using STATA/SE (ver 10.1).
Results: About half of the women (53%) were <30 years of age, 63% had <11 years of schooling, 69% were
unemployed and 37% lived in a shack. Seven percent of women had a viral load >400 copies/ml at 24 weeks and
37% had incomplete adherence at one or more visits. Incomplete adherence was associated with less education (p =
0.01) and lack of financial support from a partner (p = 0.02) after adjustment for confounders. Only when adherence
levels dropped below 80% was there a significant association with viremia in the group overall (p = 0.02) although
adherence <95% was associated with viremia in the sdNVP-exposed group (p = 0.03). The main reasons for
incomplete adherence were being away from home, busy with other things and forgetting to take their medication.
Conclusion: Virologic response to NNRTI-treatment in the cohort was excellent. However, women who received
sdNVP were at greater risk of virologic failure when adherence was <95%. Women exposed to sdNVP, and those
with less education and less social support may benefit from additional adherence counseling to ensure the long-
term success of ART. More than 80% adherence may be sufficient to maintain virologic suppression on NNRTI-
based regimens in the short-term, however complete adherence should be encouraged.
Background
National and international organizations have com-
mitted to support antiretroviral treatment (ART) pro-
grams in sub-Saharan Africa (SSA) [1,2]. More than
60% of HIV-infected adults in SSA are women, who are
disproportionately affected by the HIV-1 epidemic for
both biological and socio-cultural reasons [1,3,4].
Although women are more likely to seek healthcare and
initiate ART earlier than men, [4,5] they may be more
likely to show incomplete adherence and discontinue
ART during the first year on therapy [6]. Women’s
adherence to ART may be compromised by child-care
responsibilities and dependency ratios, [7,8] economic
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adherence to ART increases women’s risk of virologic
failure and subsequent clinical progression.
The association between adherence and virologic out-
come is complex [10]. Earlier, unboosted protease inhibi-
tor-based ART regimens required more than 95%
adherence to ensure virologic suppression [11]. With
today’s non-nucleoside reverse transcriptase inhibitor
(NNRTI)- and boosted protease inhibitor-based regimens
a moderate adherence level (70-90%) may be adequate to
achieve virologic suppression [12-14]. Bangsberg and co-
workers [15] found, using a medical electronic assess-
ment (MEMS), that >75% adherence may be sufficient to
achieve virologic suppression among men receiving an
NNRTI-based regimen in San Francisco. However, for
optimal outcomes and to avoid disease progression
[16-19], maximum level of adherence (100%) should
always be the patient’s goal and the provider’sr e c o m -
mendations [12-14]. An additional factor for women that
may jeopardize ART success is prior receipt of single-
dose nevirapine (sdNVP) for prevention of mother-to-
child transmission which can select drug resistance and
jeopardize the efficacy of ART [20-23]. Little is known
about the association between adherence level and virolo-
gic suppression among women exposed to sdNVP.
In this study we examined socio-economic characteris-
tics associated with incomplete adherence, assessed
through pharmacy pill counts, and HIV RNA quantified
in plasma among women in a research cohort, from
ART initiation through 24 weeks of treatment in Johan-
nesburg, South Africa. The aim was to identify charac-
teristics of women at higher risk of incomplete
adherence to better target interventions to enhance
adherence and sustain long-term ART success.
Methods
Setting and population
HIV-infected women were recruited into an earlier
study in Johannesburg, South Africa, between July 2004
and May 2006, to assess whether previous sdNVP
impacted the efficacy of ART [23]. Women who had
received sdNVP as prophylaxis in a prior pregnancy 18
to 36 months earlier and women who had a pregnancy
in the same interval but who did not receive sdNVP
were eligible for enrollment. Other inclusion criteria
included ART-naïve and (i) presenting with CD4+ cell
counts <200 cells/mm
3, (ii) CD4+ cell counts <350
cells/mm
3 and World Health Organization (WHO)
stage III, or (iii) WHO stage IV disease. Exclusion cri-
teria were (i) acute hepatitis, (ii) elevated liver function
test values or (iii) a history of nevirapine toxicity [23].
Women were initiated onto therapy with nevirapine, sta-
vudine and lamivudine unless co-treatment for tubercu-
losis was required in which case efavirenz was
substituted for nevirapine. The primary results of this
study have been previously reported [23]. All women
provided written informed consent and the study was
approved by the Institutional Review Boards of Colum-
b i aU n i v e r s i t y ,U S Aa n dt h eU n i v e r s i t yo ft h eW i t w a -
tersrand, South Africa.
Study procedures
A baseline questionnaire was administered at enrolment
prior to treatment initiation including questions on edu-
cation level, socio-economic indicators, household mem-
bers, previous pregnancies, previous live births and
number of living children, marital status, quality of life
(QOL) [24-26] and exposure to sdNVP. HIV RNA viral
load (VL) and CD4+ cell counts were measured pre-
treatment and WHO clinical stage was determined.
Women attended the clinic monthly to 24 weeks and at
each visit VL was measured and an adherence assess-
m e n tw a sd o n eb yt h es t u d yp h a r m a c i s t .A tw e e k2 4 ,
another questionnaire was administered monitoring life
events and QOL since ART initiation. CD4+ cell counts
and VL ≤400 or >400 copies/ml were the primary treat-
ment outcomes.
Adherence and virologic failure assessment
Pill counts [27] were performed by the study pharma-
cist, who counted the number of remaining pills for
each drug separately at each drug refill visit. Refills were
scheduled at weeks 2, 4, 8, 12, 16, 20 and 24 from the
start of treatment. Pill count-based adherence was
assessed by calculating the average combined pill count
for the three drugs at each visit, using the formula
[Adherence = (Number of pills dispensed - Number of
pills returned) × 100)/(Number of pills prescribed daily ×
Number of days between pharmacy visits)].
In our study, the adherence level of women was
assessed at the seven time points. Patients were defined
as incompletely adherent, if they ever had an average
pill count of returning back >5% of their prescribed pills
to the pharmacy, indicating an adherence level of <95%
adherence at any visit. We also performed additional
analyses of levels of adherence indicated by the percen-
tage of returned pills from 0%, to >5%, >10%, >20% and
>30% on the outcome of VL >400 copies/ml at week 24.
This analysis was done first among all women and then
among women exposed vs. not exposed to sdNVP.
Patients were asked a battery of questions to assess
QOL, where the sum of questions varied from 12 (very
good QOL) to 55 (the poorest level of QOL). These
responses were categorized as 1) 12-23 (good), 2) 24-35
(intermediate) or 3) 36-55 (poor) to analyze the relation-
ship between QOL, adherence and virologic response.
Viral load was measured using the Roche Amplicor
assay (Roche Diagnostics, version 1.5) using the standard
El-Khatib et al. BMC Public Health 2011, 11:88
http://www.biomedcentral.com/1471-2458/11/88
Page 2 of 13assay (lower limit of detection, 400 copies/ml) before
commencement of treatment and the ultrasensitive
assay (lower limit of detection, 50 copies/ml) after com-
mencement of treatment. CD4+ cell count was mea-
sured by flow cytometry [23]. Viral load was assessed
pre-ART initiation and every four weeks until week 24
and VL >400 copies/ml was defined as virologic failure.
CD4+ cell count was assessed pre-ART initiation and
every 12 weeks [23].
Adherence support
Special attention was given to adherence counseling.
A patient contract was drawn up in which the partici-
pant agreed with the clinical staff to adhere as closely as
possible to medication guidelines. A booklet including
HIV and treatment information considered necessary
for adequate adherence was developed and participants
were evaluated for their understanding of this informa-
tion prior to starting therapy. Pill-boxes and diary cards
designed to suit the regimen were given to all partici-
pants. Each post-treatment visit included a pharmacist’s
review of dosing and adherence, a pill-count of returned
drugs, and all members of the clinical team offered sup-
port around adherence throughout the study [23].
Data analysis
Characteristics of the participants (including demo-
graphics, socio-economic and pre-treatment clinical fac-
tors) were compiled. Associations between incomplete
adherence, virologic failure and these other characteris-
tics were assessed using unadjusted odds ratios (OR)
with 95% confidence intervals (CI) and p-values. Back-
ward-selection multivariable logistic regression analysis
was performed including factors with p-values ≤0.10
and then repeated for those variables yielding p-values
≤0.05. Associations between incomplete adherence at
different thresholds and virologic failure were assessed
using unadjusted odds ratios with 95% CI. The statistical
analysis was performed using STATA/SE (ver 10.1).
Results
Characteristics of women pre-ART initiation
A total of 154 women participated in this study. Of
these, 147 (95%) had pill count assessment data for at
least five out of seven visits during the study period (i.e.
the first 24 weeks on ART); data on seven patients (5%)
w e r em i s s i n gf o rm o r et h a nf i v ev i s i t sa n dt h e s ew e r e
excluded from the final analysis. The socio-economic
and clinical characteristics of these seven women, did
not differ from the women included in the analysis (data
not shown). Most of the 147 women were born in South
Africa (88%), 53% were below 30 years of age, and 63%
had less than 11 years of schooling. In terms of income,
69% were unemployed and one third (37%) lived in an
informal dwelling (shack). Most (83%) women reported
being single, 75% had been pregnant at least twice and
40% had at least two living children. When we asked
about financial support from a partner or a husband,
less than half of single women (38%) and a majority of
married women (84%) reported receipt of support. The
majority had more than four of the pre-specified house-
hold assets: indoor tap water (50%), toilet (42%), electri-
city (84%), a refrigerator (66%), radio (82%), TV (82%)
or a landline telephone (11%), defining higher socio-
economic status. Seventy percent had disclosed their
HIV status to someone at home and 85% had a treat-
ment buddy. Ninety women had been exposed to
sdNVP in their previous pregnancy. The median levels
of VL and CD4 cell count pre-ART initiation were
110,000 copies/ml (range 760 - >750,000) and 166 cells/
μl (range 2 - 430) respectively. Less than a quarter
(23%) scored poorly on QOL assessments at baseline.
Risk factors for incomplete adherence
Fifty-five patients (37%) demonstrated incomplete adher-
ence, as defined by ever returning >5% of their pills at any
visit through 24 weeks. Univariable analysis examining pre-
ART factors associated with incomplete adherence is
shown in Table 1. In multivariable analysis, two factors
remained significantly associated with incomplete adher-
ence, namely, education level ≤grade 11 (OR = 2.6; 95% CI
1.2-5.6; p = 0.01) and not receiving financial support from a
partner or a husband (OR = 2.3; 95% CI 1.1-4.8; p = 0.02).
Women who had received sdNVP as prophylaxis in a prior
pregnancy were less likely to demonstrate incomplete
adherence (OR = 0.5; 95% CI 0.2-1.0; p = 0.05) but this
association did not persist after adjustment for confounders.
Characteristics reported at 24 weeks were also investi-
gated as potential correlates of incomplete adherence
(Table 2). The remaining risk factors associated with a
trend towards incomplete adherence with p-values ran-
ging from 0.06 to 0.10 were: birth outside South Africa,
living in informal housing, not having a water source
inside the home, low socio-economic status, and report-
ing a divorce or separation during first 24 weeks on ART.
Risk factors for viral load >400 copies/ml at week 24
Eleven patients (7%) had VL >400 copies/ml at 24 weeks,
six of whom (55%) were considered to be incompletely
adherent during the study period. As shown in Table 3
there were trends between the viral outcome and incom-
plete adherence during the first 24 weeks on therapy
(OR = 2.1; 95% CI 0.5-9.3; p = 0.33), an education level
below or equal to grade 11 (OR = 2.9; 95% CI 0.6-28.0;
p = 0.21), living in an informal settlement (OR = 2.2; 95%
CI 0.5-9.6; p = 0.21) and a death in the family during the
first 24 weeks on ART (OR = 3.3; 95% CI 0.7-14.0; p =
0.06). As has been reported previously, there was no
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Page 3 of 13Table 1 Pre-antiretroviral therapy (ART) characteristics and incomplete adherence over first 24 weeks of therapy (ever
with pill count <95% past 24 weeks)
Number (%) of those with
complete adherence (n = 92)
Number (%) of those with
incomplete adherence
(n = 55)
Univariable
odds ratio
(95% CI);
p-value
Demographics Born in South Africa
No (18; 12%) 8 (9%) 10 (18%) 1
Yes (128; 88%) 83 (91%) 45 (82%) 0.4 (0.2-1.2);
0.10
Age (years)
<30 (78; 53%) 50 (54%) 28 (51%) 1
≥30 (69; 47%) 42 (46%) 27 (49%) 1.2 (0.6-2.2);
0.69
Education level
> grade 11 (54; 37%) 41 (45%) 13 (24%) 1
≤ grade 11 (91; 63%) 50 (55%) 41 (76%) 2.6 (1.2-5.6);
0.01
Marital status
Single/divorced/widow (122; 83%) 74 (80%) 48 (87%) 1
Married/partner (25; 17%) 18 (20%) 7 (13%) 0.6 (0.2-1.5);
0.29
Socio-economic status (SES) Employed
No (101; 69%) 64 (70%) 37 (67%) 1
Yes (46; 31%) 28 (30%) 18 (33%) 1.1 (0.5-2.3);
0.77
Type of housing
House/flat/rented room (93; 63%) 63 (68%) 30 (55%) 1
Shack/outbuilding (54; 37%) 29 (32%) 25 (45%) 1.8 (0.9-3.6);
0.09
Number of children living at home
0-1 child (89; 61%) 57 (62%) 32 (58%) 1
≥ 2 children (58; 39%) 35 (38%) 23 (42%) 1.2 (0.6-2.3);
0.65
Lack of financial support from partner/husband
Support (67; 45%) 49 (53%) 18 (33%) 1
Lack of support (80; 55%) 43 (47%) 37 (67%) 2.3 (1.1-4.8);
0.02
Water source inside home
No (74; 50%) 41 (45%) 33 (60%) 1
Yes (73; 50%) 51 (55%) 22 (40%) 0.5 (0.3-1.1);
0.07
Toilet at home
No (86; 58%) 51 (55%) 35 (64%) 1
Yes (61; 42%) 41 (45%) 20 (36%) 0.7 (0.4-1.4);
0.33
Electricity at home
No (23; 16%) 13 (14%) 10 (18%) 1
Yes (124; 84%) 79 (86%) 45 (82%) 0.7 (0.3-1.8);
0.51
Refrigerator at home
No (50; 34%) 27 (29%) 23 (42%) 1
Yes (97; 66%) 65 (71%) 32 (58%) 0.6 (0.3-1.2);
0.12
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with pill count <95% past 24 weeks) (Continued)
Radio at home
No (28; 19%) 15 (16%) 13 (24%) 1
Yes (119; 81%) 77 (84%) 42 (76%) 0.6 (0.3-1.5);
0.28
TV at home
No (27; 18%) 12 (13%) 15 (27%) 1
Yes (120; 82%) 80 (87%) 40 (73%) 0.4 (0.2-1.0);
0.03
Landline telephone
No (131; 89%) 82 (89%) 49 (89%) 1
Yes (16; 11%) 10 (11%) 6 (11%) 1.0 (0.3-2.9);
0.99
Pre-treatment clinical characteristics Exposed to
sdNVP
No (57; 39%) 30 (33%) 27 (49%) 1
Yes (90; 61%) 62 (67%) 28 (51%) 0.5 (0.2-1.0);
0.05
VL level, pre-ART (copies/ml) 127,500 97,000
Median (range) (760 - >750,000) (6,600 - >750,000) p = 0.17
CD4 level (cells/μl)
Median (range) 155 (7 - 430) 189 (2 - 324) p = 0.16
Felt too sick to go to work or to do the daily
activities, during the last 30 days
No (104; 71%) 64 (70%) 40 (73%) 1
Yes (43; 29%) 28 (30%) 15 (27%) 0.9 (0.4-1.8);
0.68*
Traditional medicine/herbs in the last 3 months
No (126; 87%) 79 (86%) 47 (89%) 1
Yes (19; 13%) 13 (14%) 6 (11%) 0.8 (0.3-2.2);
0.63
Quality of life
Good (score 12-23) (38; 26%) 27 (29%) 11 (20%) 1
Intermediate (score 24-35) (75; 51%) 43 (47%) 32 (58%) 1.8 (0.8-4.3);
0.16
Poor (score 36-55) (34; 23%) 22 (24%) 12 (22%) 1.3 (0.5-3.6);
0.57
Disclosure and social support Disclosed HIV status
No (44; 30%) 27 (29%) 17 (31%) 1
Yes (102; 70%) 65 (71%) 37 (69%) 0.9 (0.4-1.9);
0.79
Treatment buddy
No (22; 15%) 11 (12%) 11 (20%) 1
Yes (125; 85%) 81 (88%) 44 (80%) 0.5 (0.2-1.4);
0.19
Another adult at home living with HIV
No (46; 57%) 29 (60%) 17 (51%) 1
Yes (35; 43%) 19 (40%) 16 (49%) 1.4 (0.5-3.9);
0.50*
Another child at home living with HIV
No (12; 12%) 9 (15%) 3 (8%) 1
Yes (87; 88%) 53 (85%) 34 (92%) 1.9 (0.4-11.8);
0.53*
TV, television, sdNVP, single dose nevirapine; VL, viral load; ART, antiretroviral therapy.
* 2-sided Fisher’s exact test.
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Page 5 of 13significant difference in viral suppression between women
exposed to sdNVP 18-36 months earlier relative to exposed
women with a pregnancy within the same interval [23].
Different adherence levels and viral load >400 copies/ml
at week 24
Correlations between VL >400 copies/ml at week 24 and
adherence defined using varying thresholds are shown in
T a b l e4 a .I nt h eg r o u po v e r a l l ,t h e r ew a sas i g n i f i c a n t
association between VL >400 copies/ml and ever having
an adherence level <80% (p = 0.01) or <70% (p = 0.01).
Next, we assessed the correlation between VL >400
copies/ml and adherence defined using varying thresh-
olds stratifying women based on their exposure to
sdNVP (Table 4b). For women who had received
sdNVP, there was a significant association between VL
>400 copies/ml at week 24 and adherence levels <95%,
<90%, <80%, and <70% (p ≤ 0.03). For women who had
not been exposed to sdNVP, there was no significant
association at any threshold.
Table 2 Characteristics at 24 weeks post-antiretroviral therapy (ART) initiation and incomplete adherence (ever with
pill count <95% past 24 weeks)
Type of exposure Number (%) in group who had
complete adherence
(n = 92)
Number (%) in group who had
incomplete adherence
(n = 55)
Univariable
odds ratio
(CI 95%)
p value
Quality of life
Good (score 12-23) (95; 65%) 64 (70%) 31 (56%) 1
Intermediate (score 24-35) (45; 31%) 25 (27%) 20 (36%) 1.6 (0.8-3.4); 0.18
Poor (score 36-55) (6; 4%) 2 (2%) 4 (8%) 4.1 (0.5-47.2);
0.18*
Life events since ART initiation Moved to a
new accommodation
No (113; 77%) 73 (80%) 40 (73%) 1
Yes (33; 23%) 18 (20%) 15 (27%) 1.5 (0.7-3.4); 0.30
Lost job
No (138; 95%) 88 (97%) 50 (91%) 1
Yes (8; 5%) 3 (3%) 5 (9%) 2.9 (0.5-19.5);
0.15*
Physically attacked
No (133; 91%) 83 (91%) 50 (91%) 1
Yes (13; 9%) 8 (8%) 5 (9%) 1.0 (0.3-3.8);
1.00*
Treated badly because of HIV status
No (129; 88%) 79 (87%) 50 (91%) 1
Yes (17; 12%) 12 (13%) 5 (9%) 0.7 (0.2-2.2);
0.60*
Got divorced/separated
No (118; 80%) 78 (85%) 40 (73%) 1
Yes (29; 20%) 14 (15%) 15 (27%) 2.1 (0.9-4.8); 0.08
Death of a child since ART initiation
No (140; 96%) 88 (97%) 52 (95%) 1
Yes (6; 4%) 3 (3%) 3 (5%) 1.7 (0.2-13.1);
0.67*
Death of a family member since ART
initiation
No (114; 78%) 72 (79%) 42 (76%) 1
Yes (32; 22%) 19 (21%) 13 (24%) 1.2 (0.5-2.6); 0.70
Cumulative number of life events
0 (63; 43%) 42 (46%) 21 (38%) 1
1 (52; 36%) 34 (37%) 18 (33%) 1.1 (0.5-2.3); 0.89
2 (15; 10%) 7 (8%) 8 (15%) 2.3 (0.7-7.3); 0.15
≥3 (16; 11%) 8 (9%) 8 (14%) 2.0 (0.6-6.2); 0.22
ART, antiretroviral therapy.
* 2-sided Fisher’s exact test.
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Page 6 of 13Table 3 Associations between pre-ART characteristics and viral load >400 copies/ml at week 24
Type of exposure Number (%) in women with VL≤400
copies/ml at week 24 (%)
Number (%) in women with VL > 400
copies/ml at week 24 (%)
Univariable odds
ratio (CI 95%)
p-value
Pre-ART initiation (n;%)
Demographics
Ever reported pill count level
<95% over 24 weeks
No (92; 63%) 87 (64%) 5 (45%) 1
Yes (55; 37%) 49 (36%) 6 (55%) 2.1 (0.5-9.3); 0.33*
Born in South Africa
No (18; 12%) 15 (11%) 3 (27%) 1
Yes (128; 88%) 120 (89%) 8 (73%) 0.3 (0.1-2.2); 0.14*
Age (years)
<30 (78; 53%) 70 (51%) 8 (72.7%) 1
≥30 (69; 47%) 66 (49%) 3 (27.3%) 0.4 (0.1-1.7); 0.22*
Education level
> grade 11 (54; 37%) 52 (39%) 2 (18%) 1
≤ grade 11 (91; 63%) 82 (61%) 9 (82%) 2.9 (0.6-28.0); 0.21*
Marital status
Single/divorced/widow (122;
83%)
114 (84%) 8 (73%) 1
Married/partner (25; 17%) 22 (16%) 3 (27%) 1.9 (0.3-8.9); 0.40*
Socio-economic status (SES)
Employed
No (101; 69%) 95 (70%) 6 (55%) 1
Yes (46; 31%) 41 (30%) 5 (45%) 1.9 (0.4-8.0); 0.32*
Type of housing
House/flat/rented room (93;
64%)
88 (65%) 5 (45%) 1
Shack/outbuilding (54; 37%) 48 (35%) 6 (55%) 2.2 (0.5-9.6); 0.21*
Number of children living at
home
0-1 child (89; 60%) 80 (59%) 9 (82%) 1
≥ 2 children (58; 40%) 56 (41%) 2 (18%) 0.3 (0-1.6); 0.20*
Lack of financial support from
partner/husband
Support (67; 45%) 62 (45%) 5 (45%) 1
No support (80; 55%) 74 (54%) 6 (55%) 1.00 (0.2-4.1); 1.00*
Water source inside home
No (74; 50%) 68 (50%) 6 (55%) 1
Yes (73; 50%) 68 (50%) 5 (45%) 0.8 (0.2-3.5); 1.00*
Toilet at home
No (86; 59%) 78 (57%) 8 (73%) 1
Yes (61; 41%) 58 (43%) 3 (27%) 0.5 (0.1-2.2); 0.36*
Electricity at home
No (23; 16%) 22 (16%) 1 (9%) 1
Yes (124; 84%) 114 (84%) 10 (91%) 1.9 (0.2-87.5); 1.0*
Refrigerator at home
No (50; 34%) 47 (35%) 3 (27%) 1
Yes (97; 66%) 89 (65%) 8 (73%) 1.4 (0.3-8.6); 0.75*
Radio at home
No (28; 19%) 26 (19%) 2 (18%) 1
Yes (119; 81%) 110 (81%) 9 (82%) 1.1 (0.2-10.7); 1.00*
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Page 7 of 13Table 3 Associations between pre-ART characteristics and viral load >400 copies/ml at week 24 (Continued)
TV at home
No (27; 18%) 25 (18%) 2 (18%) 1
Yes (120; 82%) 111 (82%) 9 (82%) 1.0 (0.2-10.2); 1.00*
Landline telephone
No (131; 89%) 121 (89%) 10 (91%) 1
Yes (16; 11%) 15 (11%) 1 (9%) 0.8 (0-6.5); 1.00*
Pre-treatment clinical
characteristics
Exposed to sdNVP
No (57; 39%) 51 (38%) 6 (55%) 1
Yes (90; 61%) 85 (62%) 5 (45%) 0.5 (0.1-2.1); 0.34*
VL level (copies/ml) pre-ART
Median (range) 110,000
(760 - >750,000)
92,300
(6,600 - 359,000)
p = 0.34
CD4 cell count - pre-ART
Median (range) 164 (2 - 430) 191 (7 - 355) p = 0.91
Quality of life (pre-ART)
Good (score 12-23) (38; 26%) 34 (25%) 4 (36%) 1
Intermediate (score 24-35) (75;
51%)
70 (51%) 5 (46%) 0.6 (0.1-3.3); 0.48*
Poor (score 36-55) (34; 23%) 32 (24%) 2 (18%) 0.5 (0-4.0); 0.68*
Disclosure and social support
Disclosed HIV status
No (44; 30%) 42 (31%) 2 (20%) 1
Yes (102; 70%) 94 (69%) 8 (80%) 1.8 (0.3-17.9); 0.72*
Treatment buddy
No (22; 15%) 21 (15%) 1 (9%) 1
Yes (125; 85%) 115 (85%) 10 (91%) 1.8 (0.2-93.0); 1.00*
Another adult at home, living
with HIV
No (46; 57%) 43 (57%) 3 (50%) 1
Yes (35; 43%) 32 (43%) 3 (50%) 1.3 (0.2-10.7); 1.00*
Another child at home, living
with HIV
No (12; 12%) 12 (13%) 0 1
Yes (87; 88%) 79 (87%) 8 (100%) NA; 0.59*
At week 24
Quality of life (post-ART)
Good (score 12-23) (95; 65%) 88 (65%) 7 (64%) 1
Intermediate (score 24-35) (45;
31%)
42 (31%) 3 (27%) 0.9 (0.1-4.2); 1.00*
Poor (score 36-55) (6; 4%) 5 (4%) 1 (9%) 2.5 (0-27.4); 0.40*
Moved to a new
accommodation
No (113; 77%) 105 (78%) 8 (73%) 1
Yes (33; 23%) 30 (22%) 3 (27%) 1.3 (0.2-5.9); 0.71*
Lost job
No (138; 95%) 128 (95%) 10 (91%) 1
Yes (8; 5%) 7 (5%) 1 (9%) 1.8 (0-16.7); 0.47*
Physically attacked
No (133; 91%) 122 (90%) 11 (100%) 1
Yes (13; 9%) 13 (10%) 0 NA
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Potential barriers to adherence endorsed by study parti-
cipants are shown in Figure 1. The women reported
three main reasons for missing their medication: being
away from home, being busy with other things and sim-
ply forgetting. The most common reason for missing
pills, viz being away from home, varied in importance
over the first 24 weeks. Other reasons for missing daily
medications remained similar over weeks 2-20 diminish-
ing in importance by week 24.
Discussion
In this cohort of women starting ART in Johannesburg
and who received extensive adherence support, we
explored the association between socio-economic char-
acteristics, adherence and virologic failure during the
first 24 weeks of treatment. There was a high level of
adherence despite the social and economic challenges
faced by these participants, many of whom were single
mothers living in disadvantaged economic circum-
stances. These observations are consistent with other
studies from SSA [28-31] and reflect patients’ commit-
ment to HIV care in South Africa [28].
Reduced adherence, measured as a percent of doses
missed in a given time period, has been associated with
virologic failure. The relationship between adherence
and virologic failure appears to be affected by the classes
of drugs used and may differ between early and later
treatment [32,33]. In our data, it appeared that previous
use of sdNVP may affect the relationship between
adherence and virologic failure of an NNRTI-containing
regimen. In the total study population, less than 80%
adherence was significantly associated with virologic fail-
ure. However, when women were stratified by exposure
to sdNVP, the effect of adherence on virologic failure
was strongest among the sdNVP exposed women, where
anything less than 95% adherence was significantly asso-
ciated with increased virologic failure. This might be
due to the selection and persistence of NVP resistance
mutations, albeit as minority species undetected in con-
sensus sequence [34]. In addition, the higher the level of
adherence to NNRTI-based therapy, the lower the risk
of drug resistance and virologic failure [18,32]. This
contrasts with the unexposed women among whom
there was no association between reduced levels of
adherence and virologic failure. This difference may be
a result of the relatively small number of unexposed
women (n = 57) and should be confirmed in larger pro-
spective studies. Nevertheless, our findings raise the
question of whether drug resistance selected by sdNVP
may be partially overcome with complete adherence.
The primary study was designed to assess the effect of
sdNVP on virologic response to therapy. Although expo-
sure to sdNVP in the prior 18-36 months was not asso-
ciated with a reduced likelihood of achieving and
sustaining viral suppression, women with minority
K103N mutations before treatment had a reduced dur-
ability of virologic suppression [23] as observed in other
studies [20,22,35,36]. Some studies, however, have
reported poor virologic response to NNRTI-based
Table 3 Associations between pre-ART characteristics and viral load >400 copies/ml at week 24 (Continued)
Treated badly because of HIV
status
No (129; 88%) 120 (89%) 9 (82%) 1
Yes (17; 12%) 15 (11%) 2 (18%) 1.8 (0.2-9.8); 0.62*
Got divorced/separated
No (118; 80%) 109 (80%) 9 (82%) 1
Yes (29; 20%) 27 (20%) 2 (18%) 0.9 (0.1-4.7); 1.00*
A child died since ART initiation
No (140; 96%) 130 (96%) 10 (91%) 1
Yes (6; 4%) 5 (4%) 1 (9%) 2.6 (0.1-26.6); 0.38*
Any family member died since
ART initiation
No (114; 78%) 108 (80%) 6 (55%) 1
Yes (32; 22%) 27 (20%) 5 (45%) 3.3 (0.7-14.0); 0.06*
Cumulative number of life
events
0 (63; 43%) 59 (44%) 4 (36%) 1
1 (52; 36%) 48 (36%) 4 (36%) 1.2 (0.2-6.9); 1.00*
2 (15; 10%) 14 (10%) 1 (9%) 1.1 (0-11.8); 1.00*
≥3 (16; 11%) 14 (10%) 2 (19%) 2.1 (0.2-16.3); 0.59*
TV, television, sdNVP, single dose nevirapine; VL, viral load; ART, antiretroviral therapy.
* 2-sided Fisher’s exact test.
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Page 9 of 13therapy even if exposure is quite distant [37]. These dif-
ferences between studies may, in part be explained by
different levels of adherence. If the effects of incomplete
adherence on virologic suppression depend on past drug
exposure, as suggested by our data, studies with less
attention to sustaining high levels of adherence may
detect decreased efficacy of ART among those with past
exposure to sdNVP. Since current guidelines recom-
mend that pregnant women with <350 CD4+ cells/mm
3
receive ART, rather than sdNVP, there is less basis to
be concerned about the impact of sdNVP on later treat-
ment outcomes [38]. Adherence level to ART is found
to be high among HIV infected pregnant women [39]
compared to non-pregnant women [40,41]. However,
ART is a life-time treatment and sustaining high adher-
ence level should remain the ultimate goal.
The women who had participated in the pMTCT
p r o g r a mw e r em o r el i k e l yt ob ea d h e r e n tt oA R Ti n
univariable analysis although this association did not
remain after adjustment for social characteristics.
Table 4 Correlation between different adherence levels and VL >400 copies/ml at week 24: a) among all women and
b) among women exposed vs. not exposed to sdNVP separately
a) All women
Percent adherence during any of the visits 2- 24 weeks ≤ 400 copies/ml >400 copies/ml Univariable odds ratio
(CI 95%); p value
100% (n = 28) 27 (20%) 1 (9%) 1
Ever <100% (n = 119) 109 (80%) 10 (91%) 2.5 (0.3-111.4); 0.69*
>95% (n = 92) 87 (64%) 5 (45%) 1
Ever <95% (n = 55) 49 (36%) 6 (55%) 2.1 (0.5-9.3); 0.33*
>90% (n = 105) 99 (73%) 6 (55%) 1
Ever <90% (n = 42) 37 (27%) 5 (45%) 2.2 (0.5-9.3); 0.30*
>80% (n = 122) 116 (85%) 6 (55%) 1
Ever <80% (n = 25) 20 (15%) 5 (45%) 4.8 (1.0-20.8); 0.02*
>70% (n = 137) 129 (95%) 8 (73%) 1
Ever <70% (n = 10) 7 (5%) 3 (27%) 6.9 (1.0-37.7); 0.03*
b) Exposed to sdNVP
Percent adherence during any of the visits 2- 24 weeks ≤ 400 copies/ml > 400 copies/ml Univariable odds ratio
(CI 95%); p value
100% (n = 18) 18 (21%) 0 1
Ever <100% (n = 72) 67 (79%) 5 (100%) NA: 0.58*
>95% (n = 62) 61 (72%) 1 (20%) 1
Ever <95% (n = 28) 24 (28%) 4 (80%) 10.2 (0.9-508.5); 0.03*
>90% (n = 69) 68 (80%) 1 (20%) 1
Ever <90% (n = 21) 17 (20%) 4 (80%) 16 (1.4-798.9); 0.01*
>80% (n = 75) 74 (87%) 1 (20%) 1
Ever <80% (n = 15) 11 (13%) 4 (80%) 26.9 (2.2-1341.7); <0.01*
>70% (n = 83) 80 (94%) 3 (60%) 1
Ever <70% (n = 7) 5 (6%) 2 (40%) 10.7 (0.7-112.3); 0.01*
Not exposed to sdNVP
≤ 400 copies/ml > 400 copies/ml Univariable odds ratio
(CI 95%); p value
100% (n = 10) 9 (18%) 1 (17%) 1
Ever <100% (n = 47) 42 (82%) 5 (83%) 1.1 (0.1-56.2); 1.00*
>95% (n = 30) 26 (51%) 4 (67%) 1
Ever <95% (n = 27) 25 (49%) 2 (33%) 0.5 (0-4.1); 0.67*
>90% (n = 36) 31 (61%) 5 (83%) 1
Ever <90% (n = 21) 20 (39%) 1 (17%) 0.3 (0-3.1); 0.40*
>80% (n = 47) 42 (82%) 5 (83%) 1
Ever <80% (n = 10) 9 (18%) 1 (17%) 0.9 (0-10.0); 1.00*
>70% (n = 54) 49 (96%) 5 (83%) 1
Ever <70% (n = 3) 2 (4%) 1 (17%) 4.9 (0.1-106.0); 0.29*
sdNVP, single dose nevirapine; VL, viral load.
* 2-sided Fisher’s exact test.
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may provide women with information about ART and
a d h e r e n c ea ss h o w ni nas t u d yi nU g a n d a[ 4 2 ] .
Another study [43] at a rural district hospital in South
Africa demonstrated that women provided with part-
ner support and complete pMTCT information were
more likely to take sdNVP. Thus, programs that pro-
vide sdNVP for pMTCT and provide women with
increased treatment education, information and sup-
port are likely to achieve better adherence on ART.
Here, women, with less education were at higher risk
for incomplete adherence. Other studies of women
[44] and of men and women [45] found independent
associations between education, health literacy and
adherence to ART. An additional concern is women’s
understanding of their children’s treatment needs,
where poor education may pose an additional risk for
inadequate administration of ART to their infected
children [46].
In Johannesburg, less education, living in an informal
setting and providing care for at least two children with
uncertain partner support, were each associated with
reduced adherence and an increased need for support
[47]. Ware and co-workers [48] found, in a large ethno-
graphic study in Nigeria, Tanzania and Uganda, that
social support enhances adherence. Also Merenstein and
co-workers [7] found that having the sole responsibility
for a child reduces adherence among women in the Uni-
ted States. Lack of potable water at home as reported by
Ellis and co-workers in Nairobi was associated with
incomplete adherence among both adults and children
[49]. In this study, we observed that patients with low
socio-economic status, assessed by living in an informal
dwelling, the absence of a TV or lack of potable water
at home were each associated with incomplete adher-
ence although these did not retain significance in the
final model, possibly because of the small sample size.
The three main reasons for missing pills were being
away from home, being busy with other things and sim-
ply forgetting, which are consistent with the findings of
a review by Mills and co-workers [50].
There are several limitations to the generalizability of
this study. Postpartum women are a vulnerable popula-
tion who may have particular difficulty in obtaining
access to ART due to financial challenges as described
by Rosen and co-workers [51]. Here we followed a rela-
tively small number of women for only six months and
did not monitor changes in socioeconomic status, rela-
tionships, employment or depression over time. Rather,
we relied on baseline responses and recall at six months.
Reimbursement for transport costs, estimated to be
~25% of the patients’ cost of ART [51], may have
improved adherence to treatment [52]. In addition, this
was a clinical research study in which attention and
resources were devoted to reinforcing adherence [53], so
it is likely that incomplete adherence may be more pre-
valent in a routine HIV care setting. Further limitations
include focus only on a single measure of adherence
and uncertain validity of some of the co-factors investi-
gated, including QOL. Adherence to ART is a dynamic
process influenced by psychosocial and socio-economic
factors that need further investigation [54].
Conclusions
In conclusion, women receiving an NNRTI-based regi-
men may achieve virologic suppression with >80%
adherence. However, higher levels of adherence may be
necessary among women who have been exposed to
Figure 1 Percentage of the most frequent reasons for missing pills over weeks 2-24.
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Page 11 of 13sdNVP. Women starting on ART with less education
and lower socio-economic level were also at a higher
risk of incomplete adherence to ART over the first six
months of treatment and special adherence counseling
and interventions may be needed to ensure sufficient
support for long-term sustainability of treatment
response among these women.
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